Login / Signup

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Ken TakahashiYosuke SetoKoutaroh OkadaShinya UematsuKen UchiboriMika TsukaharaTomoko Oh-HaraNaoya FujitaNoriko YanagitaniMakoto NishioKenichi OkuboRyohei Katayama
Published in: Thoracic cancer (2020)
ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK-tyrosine kinase inhibitor (TKI) treatment. Ceritinib and brigatinib are potential overcoming drugs against ALK I1171S + G1269A double mutation.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • risk assessment
  • climate change
  • drug induced